{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "esgPopulated": false, "market": "hk_market", "longName": "Innovent Biologics, Inc.", "marketState": "CLOSED", "regularMarketPrice": 39.75, "messageBoardId": "finmb_141109936", "exchange": "HKG", "shortName": "INNOVENT BIO", "exchangeTimezoneShortName": "HKT", "exchangeTimezoneName": "Asia/Hong_Kong", "regularMarketChangePercent": 1.923077, "gmtOffSetMilliseconds": 28800000, "fiftyTwoWeekLowChange": 20.89, "fiftyTwoWeekLowChangePercent": 1.1076351, "fiftyTwoWeekRange": "18.86 - 47.95", "fiftyTwoWeekHighChange": -8.200001, "fiftyTwoWeekHighChangePercent": -0.17101148, "fiftyTwoWeekLow": 18.86, "fiftyTwoWeekHigh": 47.95, "earningsTimestamp": 1680001140, "earningsTimestampStart": 1680001140, "earningsTimestampEnd": 1680001140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.57, "epsForward": -0.9, "epsCurrentYear": -1.47, "firstTradeDateMilliseconds": 1540949400000, "priceHint": 3, "regularMarketChange": 0.75, "regularMarketTime": 1683878916, "regularMarketDayHigh": 40.5, "regularMarketDayRange": "38.7 - 40.5", "regularMarketDayLow": 38.7, "regularMarketVolume": 8341627, "regularMarketPreviousClose": 39.0, "bid": 39.75, "ask": 39.8, "bidSize": 0, "askSize": 0, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 40.25, "averageDailyVolume3Month": 7444003, "averageDailyVolume10Day": 6389836, "priceEpsCurrentYear": -27.040815, "sharesOutstanding": 1534409984, "bookValue": 6.993, "fiftyDayAverage": 39.337, "fiftyDayAverageChange": 0.4129982, "fiftyDayAverageChangePercent": 0.010498975, "twoHundredDayAverage": 34.59025, "twoHundredDayAverageChange": 5.159752, "twoHundredDayAverageChangePercent": 0.14916782, "marketCap": 60992798720, "forwardPE": -44.166668, "priceToBook": 5.6842556, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "symbol": "1801.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "168 Dongping Street", "address2": "Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 6956 6088", "fax": "86 512 6956 6088", "website": "https://www.innoventbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.", "fullTimeEmployees": 5294, "companyOfficers": [{"maxAge": 1, "name": "Dr. De-Chao  Yu Ph.D.", "age": 58, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": {"raw": 3792736, "fmt": "3.79M", "longFmt": "3,792,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Hao Xi  Ede", "age": 63, "title": "CFO & Exec. Director", "yearBorn": 1959, "fiscalYear": 2021, "totalPay": {"raw": 780793, "fmt": "780.79k", "longFmt": "780,793"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Yong Jun  Liu M.D., Ph.D.", "age": 53, "title": "Pres", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Changshou  Gao Ph.D.", "title": "Sr. VP & CTO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Vivian  Zhang", "title": "Chief People Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Min  Liu", "title": "Chief Commercial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dongming  Wang", "title": "Sr. VP of Quality", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Blake  Salisbury", "title": "Sr. VP of Bus. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Yanju  Wang", "age": 33, "title": "Joint Company Sec.", "yearBorn": 1989, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lok Yee  Chan A.C.I.S., A.C.S.", "age": 32, "title": "Joint Company Sec.", "yearBorn": 1990, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}